Physician profile
Marita A Kametas
NPI 1497424873
$258,741.88
in general payments reported to CMS, 2019-2025
6 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15K · 2023: $25K · 2024: $76K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Travel and Lodging: $55K · Consulting Fee: $10K · Food and Beverage: $7,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,903.00 |
| Travel and Lodging | $55,078.23 |
| Consulting Fee | $10,330.00 |
| Food and Beverage | $7,986.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $191,943.60 | 2022-2025 | |
| Janssen Biotech, INC. | $47,640.12 | 2023-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $8,131.33 | 2023-2025 | Omvoh |
| Pfizer INC. | $6,313.07 | 2023-2025 | |
| Eli Lilly and Company | $4,601.60 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $112.16 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marita Kametas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.